Skip to main content
Premium Trial:

Request an Annual Quote

Applera Expands Access to Credit to $200M and Higher

NEW YORK, April 21 (GenomeWeb News) - Applera has entered into a five-year $200 million unsecured credit agreement with a group of lenders, according to an SEC document the company filed yesterday.


The new agreement replaces an existing $50 million revolving credit agreement that was scheduled to mature on April 20, the company said in the filing. The new credit facility, which ABI will use for general corporate purposes, can increase to $250 million as long as the company maintains a consolidated net worth of at least $900 million and a debt-to-capitalization ratio of no more than .50 to 1.00, according to the document.


Applera, which will report its financials next week, is currently debt-free and holds some $650 million in cash.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.